Our history

Araclon Biotech, company dedicated to the development of therapies and diagnostic methods for the Alzheimer's disease

Founded in 2004, the company has developed into a large research project, focused on the early diagnosis and treatment of Alzheimer’s disease. The project, which began in the University of Zaragoza, has been led from the start by Dr. D. Manuel Sarasa, who is the Chief Scientific Officer of Araclon Biotech. This project has led to a series of patents being licensed by the company, aiding Araclon’s continued development.

At the end of 2006, the company further established itself, with the help of several investors, by increasing its number of research projects, creating a new organisation, clarifying its business and research strategy, and planning the construction of its own R+D+i laboratory. In 2008, the company gained support from the Government of La Rioja, allowing it to begin a new line of research in its CIBIR facilities.

In 2009, Araclon obtained its first European patent for a vaccine against Alzheimer’s disease. The year 2010 saw the first regulatory preclinical test of an immunotherapy against Alzheimer’s disease take place.

In 2012 GRIFOLS, a world leader in blood derived medical products, acquired 51% of Araclon Biotech insuring the continuity of the company and it’s projects.This participation as a shareholder, allows Grifols to promote an Alzheimer’s research strategy by comprehensively addressing this degenerative disease: early diagnosis, new treatments with plasma derivatives, hoped to slow the progression of the disease, and development of a vaccine as a preventative measure.

In 2014, Araclon began Phase I clinical trials for an active immunotherapy against Alzheimer’s disease.